California Institute of Technology | Evolved Enzymes Build TB Antibiotic Ingredient in the Desired Form, Potentially Reducing Waste

23 September 2026

California Institute of Technology news release

TB is a contagious bacterial infection that primarily affects the lungs. While curative treatments exist, more than 80% of cases occur in low- and middle-income nations, where drug-resistant strains are on the rise and the cost of medications is a burden. A new class of antibiotics has shown promise against multidrug- and extensively drug-resistant TB, but its manufacturing cost is a barrier to access in poorer countries that need the treatments most.

Now, researchers have developed a method that could lower those production costs and increase access to better treatments.

Read the full news release here.

Source: Phys.org